Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adenocarcinoma, Adjunct, ameliorated, amyloid, apathy, atezolizuma, augment, authoritative, bid, Bristol, Capacity, caudate, Conquer, consecutive, deficiency, delisted, delisting, Dentistry, divestment, domain, Editor, EMD, entorhinal, ESMO, flat, Florida, Gateway, glia, homeostatic, joinder, learn, learning, missed, moca, Montreal, NSF, oCertain, oCurrent, oEven, oIf, oOur, oProduct, oThe, OTS, PD, PDAC, penny, Pfizer, posed, preplanned, progenitor, PTAP, putamen, regain, Rho, risen, ROI, sequential, Serono, signatory, SITC, stratified, striatum, stringent, subgroup, substitute, symptomatic, synaptic, UCF, UK, variously, widespread
Filing tables
Filing exhibits
VCNX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-269385, 333-264236, 333-246322 and 333-246326 on Form S-3 and Registration Statement No. 333-226964 on Form S-8 of our report dated March 31, 2023, relating to the financial statements of Vaccinex, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.
/s/ Deloitte & Touche LLP
Rochester, New York
March 31, 2023